Internal Medicine
Review: Life-threatening skin conditions presenting to critical care.
28 Sep, 2021 | 08:57h | UTCLife-threatening skin conditions presenting to critical care – BJA Education
Podcast: Diabetic Pearls.
28 Sep, 2021 | 08:53h | UTC#296 Diabetes FAQ with Dr. Jeff Colburn – The Curbsiders
M-A of randomized trials: Efficacy of exercise combined with standard treatment for depression compared to standard treatment alone.
28 Sep, 2021 | 08:55h | UTC
Commentary on Twitter
Meta-analysis: Exercise combined with standard treatments for depression is more effective than standard treatments alone. https://t.co/TlePIyvzo3 pic.twitter.com/h6eRoKFLUt
— Steve Stewart-Williams (@SteveStuWill) September 18, 2021
Improving communication of incidental imaging findings: transforming uncertainty into opportunity.
28 Sep, 2021 | 08:50h | UTCRelated:
Meta-Analysis: Incidental Findings on MRI of Apparently Asymptomatic Adults
Review: Prevalence and Outcomes of Incidental Imaging Findings
Study: Cascades of Care After Incidental Findings
Podcast: Neutropenic Fever.
28 Sep, 2021 | 08:52h | UTC#288 LIVE! Neutropenic Fever featuring Dr. Susan Seo – The Curbsiders
Updated WHO Living Guideline: Therapeutics and COVID-19.
26 Sep, 2021 | 22:16h | UTCTherapeutics and COVID-19: living guideline – World Health Organization
WHO Statement: On new recommendation for treatment of COVID-19 patients: WHO calls for equitable access to casirivimab and imdevimab for COVID-19
See also:
WHO recommends antibody treatment for COVID patients at high risk of hospital admission.
Commentary: WHO adds new recommendation for COVID-19 monoclonal antibody combo – CIDRAP
Antibiotic Overuse and Stewardship at Hospital Discharge: The Reducing Overuse of Antibiotics at Discharge (ROAD) Home Framework.
26 Sep, 2021 | 21:40h | UTC
Commentary on Twitter
Looking to improve antibiotic use at discharge? Check out our ROAD Home Framework: Reducing Overuse of Antibiotics at Discharge Home. 🔥🔥🔥 at CID. https://t.co/mTKlaNerpC Excited for my first pub with the amazing @EmilySpivak and Adam Hersh! #stewarship @IDSAInfo pic.twitter.com/BMkD1M6Rqs
— Valerie Vaughn (@ValerieVaughnMD) September 23, 2021
[Preprint] PRINCIPLE RCT: Colchicine does not improve time to recovery in outpatients with Covid-19 at higher risk of complications.
24 Sep, 2021 | 10:13h | UTC
Commentary on Twitter
While COLCORONA trial found limited evidence that colchicine may reduce COVID-19 related hospitalisation/death
🆕💥💥@TrialPrinciple preprint
Colchicine did NOT improve time to recovery in people at higher risk of complications w COVID-19 in the communityhttps://t.co/2sUoeD7sGV pic.twitter.com/fi2THbxewW— Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 (@ABsteward) September 23, 2021
WHO recommends antibody treatment for COVID patients at high risk of hospital admission.
24 Sep, 2021 | 10:11h | UTCOriginal article and infographic: A living WHO guideline on drugs for covid-19 – The BMJ
Expert panel recommends against use of race in assessment of kidney function.
24 Sep, 2021 | 09:01h | UTCExpert panel recommends against use of race in assessment of kidney function – STAT
Commentary on Twitter
A Unifying Approach for GFR Estimation: Recommendations of the @nkf – @ASNKidney Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease https://t.co/0qt8F7l9Wm (FREE)#KidneyDisease #HealthEquity pic.twitter.com/QVkMnsBA6B
— AJKD (@AJKDonline) September 23, 2021
COVID-19 vaccines: Keeping pace with SARS-CoV-2 variants.
24 Sep, 2021 | 10:02h | UTCCOVID-19 vaccines: Keeping pace with SARS-CoV-2 variants – Cell
Commentary on Twitter
https://twitter.com/Sri_Baqri/status/1438865999281983490
Review | Interplay between endocrinology, metabolism, and COVID-19 infection.
24 Sep, 2021 | 10:00h | UTCInterplay between endocrinology, metabolism, and COVID-19 infection – Clinical Medicine Journal
Landmark articles suggest eliminating race in the estimation of kidney function.
24 Sep, 2021 | 09:03h | UTCStudy 2: Race, Genetic Ancestry, and Estimating Kidney Function in CKD – New England Journal of Medicine
Commentaries:
Remove Race From Equation Used to Assess Kidney Function, Researchers Say – AJMC
Commentary on Twitter
Honored to contribute to the NEW 2021 CKD-EPI #race-free #eGFR equation in our latest research published in @NEJM today. I learned a ton about equations. Importantly, the main lesson is that #race should NOT be incorporated into #biological tools. https://t.co/RvfWWwGOox pic.twitter.com/Xub23AUXht
— Amaka Eneanya, MD, MPH (@AmakaEMD) September 23, 2021
Cohort Study: Insulin resistance linked to increased risk of major depressive disorder.
24 Sep, 2021 | 08:59h | UTCCommentaries:
Insulin Resistance Linked to Major Depressive Disorder, Dutch Study Finds – Psychiatric News Alert
Insulin resistance doubles risk of major depressive disorder – Stanford Medicine
Clinical practice guideline on immune checkpoint inhibitor-related adverse events.
24 Sep, 2021 | 08:55h | UTCRelated:
NCCN Guidelines Insights: Management of Immunotherapy-Related Toxicities (several resources on the subject)
Immune Checkpoint Inhibitor Myocarditis: Pathophysiological Characteristics, Diagnosis, and Treatment (several resources on the subject)
WHO global antimicrobial resistance surveillance for Neisseria gonorrhoeae 2017–18 – In many countries, ciprofloxacin resistance was exceedingly high, and decreased susceptibility or resistance to ceftriaxone and cefixime continued to emerge.
24 Sep, 2021 | 08:53h | UTC
[Preprint] Third dose of Sinopharm inactivated SARS-CoV-2 vaccine induces robust B and T cell responses.
23 Sep, 2021 | 10:18h | UTCCommentaries:
Sinopharm’s COVID booster reverses antibody decline, enhances cell-based responses – study – Reuters
Cochrane Special Collection | De-implementation of low-value health care: resource prioritization in the COVID-19 pandemic era.
23 Sep, 2021 | 10:13h | UTCEditorial: Making wise choices about low‐value health care in the COVID‐19 pandemic – Cochrane Library
Commentary: Choosing health care wisely when resources are scarce – Evidently Cochrane
Commentaries on Twitter
📰Our new editorial @cochranecollab: Making wise choices about low‐value health care in the COVID‐19 pandemic👉https://t.co/qABVg7emRi
Linked Special Collection on low-value care: https://t.co/fstV8P8OQS#FreeAccess pic.twitter.com/h9KZGUm2kp
— Juan Franco 🏳️🌈 (@juan_francomd) September 22, 2021
Sadly, some medical interventions are in use despite evidence against them. With @Cochrane_SH, we have published a Special Collection of Cochrane reviews of Low Value Care interventions and described the issue in an Editorial. We cannot afford wasted HC. https://t.co/PXUhaMZud2
— Karsten Juhl Jørgensen (@KarstenJuhl) September 22, 2021
Systematic review: Clinical characteristics of multisystem inflammatory syndrome in adults.
23 Sep, 2021 | 10:12h | UTC
Commentary on Twitter
Multisystem inflammatory syndrome has been reported in adults worldwide but may be hard to distinguish from acute biphasic #COVID19 and postacute sequelae of COVID-19. More research is needed to understand this emerging clinical entity. https://t.co/OnerzsZKVB
— JAMA Network Open (@JAMANetworkOpen) September 22, 2021
ERS clinical practice guidelines on treatment of sarcoidosis.
23 Sep, 2021 | 10:00h | UTCERS clinical practice guidelines on treatment of sarcoidosis – European Respiratory Journal
Consensus Document: Evaluation and management of cancer patients presenting with acute cardiovascular disease—Part 1: acute coronary syndromes and acute pericardial diseases.
23 Sep, 2021 | 10:01h | UTCRelated:
Brazilian Cardio-oncology Guideline – 2020
Commentary on Twitter
📌Evaluation & Management of Cancer 👥presenting w/ Acute Coronary Syndromes & Acute Pericardial diseases. Consensus📝from #ACVC & the @escardio council of #CardioOncology#CardioEd #CardioTwitter #CardioOnc #EchoFirst pic.twitter.com/QSNOv7uFK7
— Diego Segura-Rodríguez (@SeguraCardio) September 19, 2021
Expert Analysis | Colchicine in acute coronary syndrome: when to commence?
23 Sep, 2021 | 09:56h | UTCColchicine in Acute Coronary Syndrome: When to Commence? – American College of Cardiology
Related:
Review: Colchicine and the heart.
M-A: Colchicine administration for percutaneous coronary intervention
M-A: Efficacy and safety of low-dose colchicine in patients with coronary disease
Meta-analysis: Colchicine reduces new cardiovascular events in patients with coronary artery disease
Expert analysis: Efficacy and safety of colchicine in patients with chronic stable coronary disease
#ESCCongress – Randomized trial: Colchicine not beneficial for patients with acute coronary syndrome
Research: Colchicine Therapy and Plaque Stabilization in Patients With Acute Coronary Syndrome
Importance of distinguishing between asthma and chronic obstructive pulmonary disease in primary care.
23 Sep, 2021 | 09:57h | UTC
Phenotypes and subphenotypes of delirium: a review of current categorizations and suggestions for progression.
23 Sep, 2021 | 09:54h | UTC
[Press release – not published yet] J&J says booster shot at two months provided 75% protection against moderate to severe COVID-19 globally and 94% of such cases in the U.S.
22 Sep, 2021 | 10:26h | UTCCommentaries:
Johnson & Johnson says additional dose boosts Covid vaccine efficacy – STAT
J&J booster 94% effective against severe COVID, company says – CIDRAP
Two dose version of Johnson & Johnson shot 94% effective against Covid-19, study finds – CNN
Commentaries on Twitter
(thread – click for more)
📍BREAKING—At last—new data on 2-doses of Johnson & Johnson's #vaccine (doses 56 days apart) is 94% effective against symptomatic #COVID19, thus comparable to Moderna/Pfizer. And 100% effective against severe COVID. Booster for 1 dose works well too. 🧵https://t.co/3nPkodOjuG pic.twitter.com/DizjWt9NYX
— Eric Feigl-Ding (@DrEricDing) September 21, 2021
(thread – click for more)
https://twitter.com/hildabast/status/1440363761299124229